Your trusted source for investing success
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New
We take a look at the latest medical device companies that received an FDA clearance, what their products are about and their stock performance.
BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced it has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration
Through the rise of bioelectronics and medtech, medical device manufacturers are claiming major market share.
From cybersecurity to bioelectronics, medical device topics are garnering increased media coverage.
By Emma Harwood
Events from 2016 will inform those of 2017, as hackers shift gears in online attacks that are becoming more and more sophisticated.
By Pia Rivera
Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).
As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on
“White hat” hackers can test cyber vulnerabilities of connected medical devices without fear of legal repercussion.
St. Jude Medical, a global medical device company, today presented favorable results from the largest observational study to date of the company’s AMPLATZER™ Amulet™ left atrial appendage occluder.
St. Jude Medical shareholders approved the merger agreement under which Abbott (NYSE:ABT) will acquire St. Jude Medical.
Short seller Muddy Waters Capital has reiterated allegations of cybersecurity vulnerability with St. Jude Medical’s cardiac devices.
The company warns that built up lithium deposits in their defibrillators’ batteries can cause them to short circuit.
St. Jude Medical, a global medical device company, today announced the United States Food and Drug Administration approval and first implant of the St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) system and its DBS directional leads, the first directional lead approved in the United States.
Johnson & Johnson is warning customers that its Animas OneTouch Ping Insulin pump can be hacked—a cybersecurity vulnerability that could be deadly.
St. Jude Medical saw its stock fall four percent after Muddy Waters published a report alleging that the medical device manufacturer had serious cyber security issues. Now, St. Jude is striking back with a lawsuit its CEO calls “critical to the entire medical device ecosystem.”
MINNEAPOLIS, MN, July 28, 2016 /PRNewswire/ – Throughout the past two decades, catheter ablation for atrial fibrillation (AF) and ventricular tachycardia (VT), two conditions characterized by irregular heartbeat, has transitioned from a relatively unproven procedure to a common and important strategy for treating these complex arrhythmias.
Minneapolis, MN, July 19, 2016 (GLOBE NEWSWIRE) — BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology information system, today announced it has issued a letter to the Company’s shareholders.
Electrophysiology devices industry is anticipated to grow at a CAGR of over 5.0% and reach over USD 6.18 billion by 2020 owing to growing old age population and frequent cardiac arrhythmias incidents.
Confronted with lagging sales figures, Reuters reports that medical device makers are beginning to increase guarantees of compensation if a product does perform as predicted. Currently, the burden of replacing medical devices typically falls to health insurers and patients, although they sometimes gain some compensation in court.
